PDCD1 and hypophysitis: For instance, hypophysitis is more prevalent following treatment with anti-CTLA-4 drugs like ipilimumab, while thyroid dysfunction is more commonly associated with anti-PD-1 drugs such as nivolumab and pembrolizumab.